Rhenman & Partners Asset Management AB Buys 5,000 Shares of Becton Dickinson and Co (NYSE:BDX)

Rhenman & Partners Asset Management AB increased its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 6.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,000 shares of the medical instruments supplier’s stock after buying an additional 5,000 shares during the quarter. Becton Dickinson and accounts for about 2.2% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 13th largest position. Rhenman & Partners Asset Management AB’s holdings in Becton Dickinson and were worth $20,161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of BDX. Ronna Sue Cohen lifted its position in shares of Becton Dickinson and by 24,129.0% during the 1st quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after buying an additional 5,710,365 shares during the period. Thoroughbred Financial Services LLC lifted its position in shares of Becton Dickinson and by 25,302.2% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock worth $99,094,000 after buying an additional 987,039 shares during the period. FMR LLC lifted its position in shares of Becton Dickinson and by 5.0% during the 1st quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after buying an additional 842,590 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Becton Dickinson and by 10.4% during the 1st quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after buying an additional 416,459 shares during the period. Finally, California Public Employees Retirement System lifted its position in shares of Becton Dickinson and by 29.9% during the 1st quarter. California Public Employees Retirement System now owns 971,355 shares of the medical instruments supplier’s stock worth $242,576,000 after buying an additional 223,484 shares during the period. Institutional investors and hedge funds own 84.80% of the company’s stock.

Shares of BDX stock traded down $3.83 on Friday, reaching $248.52. 444,489 shares of the stock were exchanged, compared to its average volume of 712,455. The company has a market capitalization of $67.33 billion, a PE ratio of 22.57, a PEG ratio of 1.91 and a beta of 1.12. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $265.87. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. The firm’s 50 day moving average price is $249.95.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $4.20 billion during the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm’s quarterly revenue was down .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.65 earnings per share. As a group, analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.24%. Becton Dickinson and’s payout ratio is currently 27.97%.

In other news, EVP Samrat S. Khichi sold 16,085 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the sale, the executive vice president now owns 12,608 shares in the company, valued at $2,958,845.44. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Simon D. Campion sold 2,903 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total value of $687,836.82. Following the sale, the executive vice president now owns 9,408 shares of the company’s stock, valued at approximately $2,229,131.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,154 shares of company stock valued at $4,955,775. 0.12% of the stock is currently owned by corporate insiders.

Several brokerages have issued reports on BDX. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Barclays upgraded Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price objective for the company in a research report on Monday, May 13th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday. Morgan Stanley lifted their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 16th. Finally, BMO Capital Markets cut their price objective on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research report on Friday, May 10th. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $263.58.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Diversification

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.